Medivation Inc.

Mr. Blickenstaff served as the President and Chief Executive Officer of Biosite Incorporated (NASDAQ: BSTE), a public medical diagnostics company, from April 1988 until its acquisition in 2007. He is also a director of several privately-held medical products companies. Prior to joining Biosite, he held various positions in finance, operations, research management, sales management, strategic planning, and marketing with Baxter Travenol, National Health Laboratories and Hybritech Incorporated. Mr. Blickenstaff received a B.A. from Loyola Marymount College and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Josee and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer. Dr. Sawyers' work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyers' key role in the clinical development of imatinib (Gleevec ), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing. Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Daniel Adams became CEO of Protein Sciences in 1995. He has previously founded and managed biopharmaceutical companies that have a combined market value of over $10 billion. He co-founded Biogen (OTC-BGEN) and served as its first President and CEO, founded and was CEO of Advanced Genetic Sciences Inc. ("AGS"), and co-founded Plant Genetic Systems in 1982. Dan holds a BA degree in Chemistry from Cornell University and a JD magna cum laude from New York University School of Law.

Tony Vernon joined Kraft Foods in August 2009 as Executive Vice President and President, Kraft Foods North America. In this role, he leads the company’s $24 billion business in the United States and Canada, based in Northfield, Illinois. Tony came to Kraft Foods from private equity firm Ripplewood Holdings, where he served since 2006 as the healthcare industry partner. In that role, he led the evaluation and investments in biotechnology, pharmaceutical and medical device companies. Prior to Ripplewood Holdings, Tony led a number of Johnson & Johnson's largest franchises during a 23-year career. He served as Company Group Chairman of DePuy Orthopedics (2004-2005), President of Centocor (2001-2004), and President of McNeil Consumer Products and Nutritionals, Worldwide and President of The Johnson & Johnson-Merck Joint Venture (1995-2001). Tony led many of J&J's largest consumer brands, including Tylenol, Motrin, Pepcid AC, Imodium and Splenda. In addition, he led the strategic evaluation, licensing and launch of Concerta and helped turn Remicade into a market leader in biologics; both of these prescription drugs are now billion dollar franchises for J&J. He also served as member of Johnson & Johnson's Group Operating Committees for Consumer Healthcare and Nutritionals, Biopharmaceuticals and Medical Devices and Diagnostics. Tony earned a bachelor’s degree in history from Lawrence University and an MBA from the Northwestern University Kellogg Graduate School of Management. Since 2006, he has served as an independent director of several consumer, biotechnology and medical device companies, including Medivation, Uluru, NovoCure, Cord Blood Registry, Disc Dynamics and Zeo Inc.